BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35171994)

  • 1. Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features.
    Cazaubiel T; Leleu X; Perrot A; Manier S; Buisson L; Maheo S; Do Souto Ferreira L; Lannes R; Pavageau L; Hulin C; Marolleau JP; Voillat L; Belhadj K; Divoux M; Slama B; Brechignac S; Macro M; Stoppa AM; Sanhes L; Orsini-Piocelle F; Fontan J; Chretien ML; Demarquette H; Mohty M; Schavgoulidze A; Avet-Loiseau H; Corre J
    Blood; 2022 Apr; 139(17):2666-2672. PubMed ID: 35171994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcriptome analysis reveals significant differences between primary plasma cell leukemia and multiple myeloma even when sharing a similar genetic background.
    Rojas EA; Corchete LA; Mateos MV; García-Sanz R; Misiewicz-Krzeminska I; Gutiérrez NC
    Blood Cancer J; 2019 Nov; 9(12):90. PubMed ID: 31748515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and cytogenetic characteristics of primary and secondary plasma cell leukemia under the new IMWG definition criteria: a retrospective study.
    Guan J; Ma J; Chen B
    Hematology; 2023 Dec; 28(1):2254556. PubMed ID: 37732631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns.
    Schinke C; Boyle EM; Ashby C; Wang Y; Lyzogubov V; Wardell C; Qu P; Hoering A; Deshpande S; Ryan K; Thanendrarajan S; Mohan M; Yarlagadda N; Khan M; Choudhury SR; Zangari M; van Rhee F; Davies F; Barlogie B; Morgan G; Walker BA
    Blood Cancer J; 2020 Jun; 10(6):70. PubMed ID: 32555163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of Circulating Plasma Cells on the Prognosis of Patients with Multiple Myeloma].
    Li F; Gao YJ; Li SS; Xi YY; Yang XW; Su YH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1771-1779. PubMed ID: 38071059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia.
    Lionetti M; Musto P; Di Martino MT; Fabris S; Agnelli L; Todoerti K; Tuana G; Mosca L; Gallo Cantafio ME; Grieco V; Bianchino G; D'Auria F; Statuto T; Mazzoccoli C; De Luca L; Petrucci MT; Offidani M; Di Raimondo F; Falcone A; Caravita T; Omede' P; Morabito F; Tassone P; Boccadoro M; Palumbo A; Neri A
    Clin Cancer Res; 2013 Jun; 19(12):3130-42. PubMed ID: 23613318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients.
    An G; Qin X; Acharya C; Xu Y; Deng S; Shi L; Zang M; Sui W; Yi S; Li Z; Hao M; Feng X; Jin F; Zou D; Qi J; Zhao Y; Tai YT; Wang J; Qiu L
    Ann Hematol; 2015 Feb; 94(2):257-64. PubMed ID: 25231928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcriptional characterization of a prospective series of primary plasma cell leukemia revealed signatures associated with tumor progression and poorer outcome.
    Todoerti K; Agnelli L; Fabris S; Lionetti M; Tuana G; Mosca L; Lombardi L; Grieco V; Bianchino G; D'Auria F; Statuto T; Mazzoccoli C; De Luca L; Petrucci MT; Morabito F; Offidani M; Di Raimondo F; Falcone A; Omede' P; Tassone P; Boccadoro M; Palumbo A; Neri A; Musto P
    Clin Cancer Res; 2013 Jun; 19(12):3247-58. PubMed ID: 23599371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic aberrations including chromosome 1 abnormalities and clinical features of plasma cell leukemia.
    Chang H; Qi X; Yeung J; Reece D; Xu W; Patterson B
    Leuk Res; 2009 Feb; 33(2):259-62. PubMed ID: 18676019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How We Manage Newly Diagnosed Multiple Myeloma With Circulating Tumor Cells.
    van de Donk NWCJ
    J Clin Oncol; 2023 Mar; 41(7):1342-1349. PubMed ID: 36450104
    [No Abstract]   [Full Text] [Related]  

  • 11. [Advances in the Diagnosis and Therapy of Primary Plasma Cell Leukemia -Review].
    Wang H; Li JY; Sun C; Zhou X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1837-1841. PubMed ID: 29262927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic profile of primary plasma cell leukemia in Korea: comparison with plasma cell myeloma.
    Lee Y; Yun J; Jeong D; Ryu S; Kwon SR; Yun H; Kim SM; Park JH; Lee DS
    Leuk Lymphoma; 2022 Feb; 63(2):385-394. PubMed ID: 34592901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical characteristics and prognosis of patients with primary plasma cell leukemia (pPCL) according to the new IMWG definition criteria.
    Yan W; Fan H; Xu J; Liu J; Li L; Du C; Deng S; Sui W; Hao M; Yi S; Zou D; Qiu L; Xu Y; An G
    Leuk Lymphoma; 2022 Dec; 63(12):2955-2964. PubMed ID: 35819882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Causes of death in primary plasma cell leukemia differ from multiple myeloma: A STROBE-compliant descriptive study based on SEER database.
    Ge X; Meng W; Wang W; Ma H; Zhao S; Cui K
    Medicine (Baltimore); 2022 Jul; 101(29):e29578. PubMed ID: 35866755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor.
    Schavgoulidze A; Talbot A; Perrot A; Cazaubiel T; Leleu X; Manier S; Buisson L; Mahéo S; Do Souto Ferreira L; Pavageau L; Hulin C; Marolleau JP; Voillat L; Belhadj K; Divoux M; Slama B; Brechignac S; Macro M; Stoppa AM; Sanhes L; Orsini-Piocelle F; Fontan J; Chretien ML; Demarquette H; Mohty M; Avet-Loiseau H; Corre J
    Blood; 2023 Mar; 141(11):1308-1315. PubMed ID: 36375118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary plasma cell leukemia presenting as a thoracic mass.
    Igala M; Bopaka RG; Khtabi W; Benchekroun S; Quessar A
    Pan Afr Med J; 2014; 19():39. PubMed ID: 25667701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic aberrations and survival in plasma cell leukemia.
    Tiedemann RE; Gonzalez-Paz N; Kyle RA; Santana-Davila R; Price-Troska T; Van Wier SA; Chng WJ; Ketterling RP; Gertz MA; Henderson K; Greipp PR; Dispenzieri A; Lacy MQ; Rajkumar SV; Bergsagel PL; Stewart AK; Fonseca R
    Leukemia; 2008 May; 22(5):1044-52. PubMed ID: 18216867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents.
    Mina R; Joseph NS; Kaufman JL; Gupta VA; Heffner LT; Hofmeister CC; Boise LH; Dhodapkar MV; Gleason C; Nooka AK; Lonial S
    Cancer; 2019 Feb; 125(3):416-423. PubMed ID: 30332496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary Plasma Cell Leukemia: Real-World Retrospective Study of 46 Patients From a Single-Center Study in China.
    Yu T; Xu Y; An G; Tai YT; Ho M; Li Z; Deng S; Zou D; Yu Z; Hao M; Anderson KC; Qiu L
    Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e652-e659. PubMed ID: 32624447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience.
    Hebraud B; Magrangeas F; Cleynen A; Lauwers-Cances V; Chretien ML; Hulin C; Leleu X; Yon E; Marit G; Karlin L; Roussel M; Stoppa AM; Belhadj K; Voillat L; Garderet L; Macro M; Caillot D; Mohty M; Facon T; Moreau P; Attal M; Munshi N; Corre J; Minvielle S; Avet-Loiseau H
    Blood; 2015 Mar; 125(13):2095-100. PubMed ID: 25636340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.